Abeona Therapeutics Stock (NASDAQ:ABEO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$5.89

52W Range

$3.05 - $9.01

50D Avg

$6.18

200D Avg

$5.75

Market Cap

$249.96M

Avg Vol (3M)

$262.38K

Beta

1.50

Div Yield

-

ABEO Company Profile


Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

84

IPO Date

Sep 19, 1980

Website

ABEO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 21Dec 20Dec 18
License and Other Revenues$3.00M$10.00M-
Foundation--$5.71M
License--$602.00K

Fiscal year ends in Dec 23 | Currency in USD

ABEO Financial Summary


Dec 23Dec 22Dec 21
Revenue$3.50M$1.41M$3.00M
Operating Income$-48.20M$-45.26M$-89.84M
Net Income$-54.19M$-31.81M$-88.61M
EBITDA$-45.00M$-44.69M$-54.05M
Basic EPS$-2.53$-4.05$-22.50
Diluted EPS$-2.53$-4.05$-22.50

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 23Nov 16, 23 | 4:26 PM
Q2 23Aug 12, 23 | 1:42 PM
Q1 23May 24, 23 | 2:54 PM

Peer Comparison


TickerCompany
CKPTCheckpoint Therapeutics, Inc.
XFORX4 Pharmaceuticals, Inc.
CALACalithera Biosciences, Inc.
MREOMereo BioPharma Group plc
RVPHReviva Pharmaceuticals Holdings, Inc.
DAWNDay One Biopharmaceuticals, Inc.
PDSBPDS Biotechnology Corporation
RGNXREGENXBIO Inc.
ADAPAdaptimmune Therapeutics plc
BDTXBlack Diamond Therapeutics, Inc.
IVVDInvivyd, Inc.
FBIOFortress Biotech, Inc.
TERNTerns Pharmaceuticals, Inc.
ACADACADIA Pharmaceuticals Inc.
CABACabaletta Bio, Inc.
INZYInozyme Pharma, Inc.
ATHAAthira Pharma, Inc.
AFMDAffimed N.V.
ANEBAnebulo Pharmaceuticals, Inc.
LPTXLeap Therapeutics, Inc.
PIRSPieris Pharmaceuticals, Inc.